Advertisement

Osteoporosis International

, Volume 7, Supplement 3, pp 213–216 | Cite as

Steroid-induced osteoporosis

  • I. R. Reid
Article

Keywords

Osteoporosis Bone Loss Salmon Calcitonin Polymyalgia Rheumatica Deflazacort 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Reid IR. Glucocorticoid osteoporosis: mechanisms and management. Eur J Endocrinol 1997 (in press).Google Scholar
  2. 2.
    Lo Cascio V, Bonucci E, Imbimbo B, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner 1990;8:39–51.CrossRefGoogle Scholar
  3. 3.
    Saito JK, Davis JW, Wasnich RD, Ross PD. Users of low-dose glucocorticoids have increased bone loss rates: a longitudinal study. Calcif Tissue Int 1995;57:115–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Laan RFJM, Vanriel PLCM, Vandeputte LBA, Vanerning LJTO, Vanthof MA, Lemmens JAM. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis: a randomized, controlled study. Ann Intern Med 1993;119:963–8.PubMedGoogle Scholar
  5. 5.
    Reid IR, Evans MC, Wattie DJ, Ames R, Cundy TF. Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients. Osteoporos Int 1992;2:103–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Reid IR, Heap SW. Determinants of vertebral mineral density in patients receiving chronic glucocorticoid therapy. Arch Intern Med 1990;150:2545–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Reid IR, Evans MC, Stapleton J. Lateral spine densitometry is a more sensitive indicator of glucocorticoid-induced bone loss. J Bone Miner Res 1992;7:1221–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Marystone JF, Barrett-Connor EL, Morton DJ. Inhaled and oral corticosteroids: their effects on bone mineral density in older adults. Am J Public Health 1995;85:1693–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Manning PJ, Evans MC, Reid IR. Normal bone mineral density following cure of Cushing’s syndrome. Clin Endocrinol 1992; 36:229–34.CrossRefGoogle Scholar
  10. 10.
    Ruegsegger P, Medici TC, Anliker M. Corticosteroid-induced bone loss: a longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol 1983;25:615–20.CrossRefPubMedGoogle Scholar
  11. 11.
    Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat JM, Setoain J. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax 1991; 46:803–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Laan RFJM, van Riel PLCM, van Erning LJThO, Lemmens JAM, Ruijs SHJ, et al. Vertebral osteoporosis in rheumatoid arthritis patients: effect of low dose prednisone therapy. Br J Rheumatol 1992;31:91–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Ross EJ, Linch DC. Cushing’s syndrome-killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982;11:646–9.CrossRefGoogle Scholar
  14. 14.
    Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995; 54:49–52.CrossRefPubMedGoogle Scholar
  15. 15.
    Shane E, Rivas M, Staron RB, Silverberg SJ, Seibel MJ, Kuiper J et al. Fracture after cardiac transplantation: a prospective longitudinal study. J Clin Endocrinol Metab 1996;81:1740–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Michel BA, Bloch DA, Wolfe F, Fries JF. Fractures in rheumatoid arthritis: an evaluation of associated risk factors. J Rheumatol 1993;20:1666–9.PubMedGoogle Scholar
  17. 17.
    Ross PD, Davis JW, Epstein RS, Wasnich RD. Preexisting fractures and bone mass predict vertebral fracture in women. Ann Intern Med 1991;114:919–23.PubMedGoogle Scholar
  18. 18.
    Reid IR, Ibbertson HK. Calcium supplements in the prevention of steroid-induced osteoporosis. Am J Clin Nutr 1986;44:287–90.PubMedGoogle Scholar
  19. 19.
    Nilsen KH, Jayson MIV, Dixon AStJ. Microcrystalline calcium hydroxyapatite compound in corticosteroid-treated rheumatoid patients: a controlled study. BMJ 1978;II:1124.CrossRefGoogle Scholar
  20. 20.
    Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;125:961–8.PubMedGoogle Scholar
  21. 21.
    Reid IR, France JT, Pybus J, Ibbertson HK. Low plasma testosterone levels in glucocorticoid-treated male asthmatics. BMJ 1985;291:574.CrossRefPubMedGoogle Scholar
  22. 22.
    Grey AB, Cundy TF, Reid IR. Continuous combined oestrogen/ progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis. Clin Endocrinol 1994;40:671–7.CrossRefGoogle Scholar
  23. 23.
    Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996; 156:1173–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535–41.CrossRefPubMedGoogle Scholar
  25. 25.
    Reid IR, King AR, Alexander CJ, Ibbertson HK. Prevention of steroid-induced osteoporosis with (3-amino-l-hydroxypropylidene)-l,l-bisphosphonate (APD). Lancet 1988;1:143–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995;99:235–42.CrossRefPubMedGoogle Scholar
  27. 27.
    Degroen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016–21.CrossRefGoogle Scholar
  28. 28.
    Hahn TJ, Hahn BH. Osteopenia in patients with rheumatic diseases: principles of diagnosis and therapy. Semin Arthritis Rheum 1976;6:165–88.CrossRefPubMedGoogle Scholar
  29. 29.
    Adachi JD, Bensen WG, Bianchi F, Cividino A, Pillersdorf S, Sebaldt RJ et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol 1996;23:995–1000.PubMedGoogle Scholar
  30. 30.
    Dykman TR, Haralson KM, Gluck OS, et al. Effect of oral 1,25-dihydroxy-vitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1984;27:1336–43.CrossRefPubMedGoogle Scholar
  31. 31.
    Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman J. Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993;328:1747–1752CrossRefPubMedGoogle Scholar
  32. 32.
    Hahn TJ, Halstead LR, Teitelbaum SL, Hahn BH. Altered mineral metabolism in glucocorticoid-induced osteopenia. J Clin Invest 1979;64:655–65.CrossRefPubMedGoogle Scholar
  33. 33.
    Di Munno O, Beghe F, Favini P et al. Prevention of glucocorticoid-induced osteopenia: effect of oral 25-hydroxy-vitamin D and calcium. Clin Rheumatol 1989;8:202–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992;327:1637–42.CrossRefPubMedGoogle Scholar
  35. 35.
    Rizzoli R, Chevalley T, Slosman DO, Bonjour JP. Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis. Osteoporos Int 1995;5:39–46.CrossRefPubMedGoogle Scholar
  36. 36.
    Rizzato G, Tosi G, Schiraldi G et al. Bone protection with salmon calcitonin (sCT) in the long-term steroid therapy of chronic sarcoidosis. Sarcoidosis 1988;5:99–103.PubMedGoogle Scholar
  37. 37.
    Luengo M, Picado C, Del Rio L et al. Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. Am Rev Respir Dis 1990;142:104–7.PubMedGoogle Scholar
  38. 38.
    Montemurro L, Schiraldi G, Fraioli P, et al. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int 1991;49:71–6.CrossRefPubMedGoogle Scholar
  39. 39.
    Dimunno O, Imbimbo B, Mazzantini M, Milani S, Occhipinti G, Pasero G. Deflazacort versus methylprednisolone in polymyalgia rheumatica: clinical equivalence and relative antiinflammatory potency of different treatment regimens. J Rheumatol 1995; 22:1492–8.Google Scholar
  40. 40.
    Krogsgaard MR, Thamsborg G, Lund B. Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica: a double blind, prospective comparison between prednisolone and deflazacort. Ann Rheum Dis 1996; 55:143–6.CrossRefPubMedGoogle Scholar
  41. 41.
    Walsh LJ, Wong CA, Pringle M, Tattersfîeld AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996;313:344–6.PubMedGoogle Scholar

Copyright information

© European Foundation for Osteoporosis 1997

Authors and Affiliations

  1. 1.Department of MedicineUniversity of AucklandAucklandNew Zealand

Personalised recommendations